EC
AXSM icon

EntryPoint Capital’s Axsome Therapeutics AXSM Stock Holding History

EntryPoint Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,263
Closed -$275K – 665
2025
Q3 		$275K Buy
2,263
+176
+8% +$19.8K 0.11% 400
2025
Q2 		$218K Sell
2,087
-80
-4% -$8.47K 0.11% 444
2025
Q1 		$253K Buy
+2,167
New +$247K 0.12% 427
2024
Q4 		– Sell
-5,156
Closed -$463K – 724
2024
Q3 		$463K Buy
5,156
+4,985
+2,915% +$435K 0.26% 74
2024
Q2 		$13.8K Sell
171
-266
-61% -$19.7K 0.02% 738
2024
Q1 		$34.9K Buy
+437
New +$36.7K 0.03% 910

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return